• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:吴培培,施朕善,李东鹏,马家芹,翟璠.宫颈癌组织ERCC1、hMSH2表达及病理特征与铂类药物抵抗的相关性研究[J].药学研究,2023,42(6):417-421[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2608次   下载 2508次 本文二维码信息
码上扫一扫!
宫颈癌组织ERCC1、hMSH2表达及病理特征与铂类药物抵抗的相关性研究
吴培培1,施朕善2,李东鹏3,马家芹2,翟璠1
字体:加大+|默认|缩小-
(1.安徽医科大学附属亳州医院妇科,安徽 亳州 236800;2.安徽医科大学附属亳州医院肿瘤科,安徽 亳州 236800;3.安徽医科大学附属亳州医院病理科,安徽 亳州 236800)
摘要:
目的 探究宫颈癌组织核苷酸切除修复交叉互补基因1(ERCC1)、错配修复基因2(hMSH2)表达与病理特征及铂类药物抵抗的相关性。方法 收集2019年1月~2022年3月我院86例宫颈癌患者病理组织为观察组,另收集同期72例因子宫肌瘤手术切除的正常宫颈组织为对照组。比较2组核苷酸切除修复交叉互补基因1、错配修复基因2表达情况,分析癌组织核苷酸切除修复交叉互补基因1、错配修复基因2表达与病理特征相关性,铂类药物抵抗患者病理特征、核苷酸切除修复交叉互补基因1、错配修复基因2表达情况及铂类药物抵抗的多因素分析,分析核苷酸切除修复交叉互补基因1、错配修复基因2表达对铂类药物抵抗的预测价值。结果 观察组核苷酸切除修复交叉互补基因1、错配修复基因2阳性率较对照组高(P<0.05);癌组织核苷酸切除修复交叉互补基因1、错配修复基因2表达与肌层浸润深度、分期、淋巴结转移有关(P<0.05);铂类药物抵抗患者与肌层浸润深度、分期、分化程度、淋巴结转移、核苷酸切除修复交叉互补基因1、错配修复基因2阳性有关(P<0.05);Logistic回归方程分析,结果显示,将肌层浸润深度、分期、分化程度、淋巴结转移控制后,癌组织核苷酸切除修复交叉互补基因1、错配修复基因2阳性仍为宫颈癌患者铂类药物抵抗的危险因素(P<0.05);ROC显示,核苷酸切除修复交叉互补基因1、错配修复基因2阳性联合预测铂类药物抵抗的AUC值最大,为0.702。结论 宫颈癌组织核苷酸切除修复交叉互补基因1、错配修复基因2呈高表达状态,且与病理特征及铂类药物抵抗有关,二者可用于预测铂类药物反应性,从而指导临床治疗。
关键词:  宫颈癌  核苷酸切除修复交叉互补基因1  错配修复基因2  病理特征  铂类药物抵抗  相关性
DOI:10.13506/j.cnki.jpr.2023.06.013
基金项目:安徽省抗癌协会重点研究课题(No.ACC0220202)
Correlation of ERCC1, hMSH2 expression with pathological characteristics and platinum resistance in cervical cancer
WU Peipei1,SHI Zhenshan2,LI Dongpeng3,MA Jiaqin2,ZHAI Fan1
(1. Department of Gynaecology,The People’s Hospital of Bozhou Affiliated Anhui University of Science&Technology,Bozhou 236800,China;2. Department of Oncology, The People’s Hospital of Bozhou Affiliated Anhui University of Science&Technology,Bozhou 236800,China;3. Department of Pathology, The People’s Hospital of Bozhou Affiliated Anhui University of Science&Technology,Bozhou 236800,China)
Abstract:
Objective To investigate the correlation between the expression of nucleotide excision repair cross complementary gene 1 (ERCC1), mismatch repair gene 2 (hMSH2) and the pathological characteristics and platinum resistance in cervical cancer. Methods The pathological tissues of 86 patients with cervical cancer in our hospital from January 2019 to March 2022 were collected as the observation group, and the normal cervical tissues of 72 patients with myoma of uterus removed during the same period were collected as the control group. Compare the expression of ERCC1 and hMSH2 in the two groups, analyze the correlation between the expression of ERCC1 and hMSH2 in cancer tissues and pathological characteristics, analyze the pathological characteristics, ERCC1 and hMSH2 expression in patients with platinum resistance, and analyze the multifactor analysis of platinum resistance, and analyze the predictive value of ERCC1 and hMSH2 expression in platinum resistance. Results The positive rates of ERCC1 and hMSH2 in the observation group were higher than those in the control group (P<0.05); The expression of ERCC1 and hMSH2 in cancer tissues was related to the depth of muscle invasion, stage and lymph node metastasis (P<0.05); Patients with platinum resistance were related to the depth of muscle invasion, stage, degree of differentiation, lymph node metastasis, ERCC1, hMSH2 positive (P<0.05); Logistic regression equation analysis showed that positive ERCC1 and hMSH2 in cancer tissues were still risk factors for platinum resistance in cervical cancer patients after controlling the depth of muscle invasion, stage, degree of differentiation and lymph node metastasis (P<0.05); ROC showed that the AUC value of ERCC1 and hMSH2 positive combined prediction of platinum resistance was the largest, 0.702. Conclusion ERCC1 and hMSH2 are highly expressed in cervical cancer tissues, and are related to pathological characteristics and platinum resistance. Both of them can be used to predict platinum drug reactivity and guide clinical treatment.
Key words:  Cervical cancer  Nucleotide excision repair cross complementary gene 1  Mismatch repair gene 2  Pathological characteristics  Platinum resistance  Relevance
今日访问量:2493    总访问量:55338936
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司